Literature DB >> 24726838

Microtubule dynamics regulates Akt signaling via dynactin p150.

Hakryul Jo1, Fabien Loison2, Hongbo R Luo3.   

Abstract

Following activation at the plasma membrane, Akt is subsequently deactivated in the cytoplasm. Although activation and deactivation of Akt must sometimes be separated in order to elicit and control cellular responses, the exact details of the spatiotemporal organization of Akt signaling are incompletely understood. Here we show that microtubule dynamics specifically modulate the deactivation phase of Akt signaling. Localization of Akt to microtubules sustains its activity, while disruption of microtubules attenuates Akt signaling independent of its initial activation. Conversely, stabilization of microtubules elevates Akt signaling both in vitro and in muscle tissues in vivo. Localization of Akt to microtubules is mediated by the microtubule binding protein dynactin p150, which is shown to be a direct target of Akt. Finally, microtubule disruption-induced Akt deactivation contributes to delayed cell cycle progression and accelerated cell death. Taken together, we revealed that, after initiation, the overall intensity and duration of oncogenic Akt signaling are determined by microtubule dynamics, a mechanism that could be exploited for therapeutic purposes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt; Cell death; Microtubules; Protein phosphorylation; Signal transduction

Mesh:

Substances:

Year:  2014        PMID: 24726838     DOI: 10.1016/j.cellsig.2014.04.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  A balancing Akt: How to fine-tune neuronal migration speed.

Authors:  Yasuhiro Itoh
Journal:  Neurogenesis (Austin)       Date:  2016-11-22

2.  Formin 1 Regulates Microtubule and F-Actin Organization to Support Spermatid Transport During Spermatogenesis in the Rat Testis.

Authors:  Nan Li; Dolores D Mruk; Elizabeth I Tang; Will M Lee; Chris K C Wong; C Yan Cheng
Journal:  Endocrinology       Date:  2016-05-04       Impact factor: 4.736

3.  Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.

Authors:  Wei Wen; Emily Marcinkowski; David Luyimbazi; Thehang Luu; Quanhua Xing; Jin Yan; Yujun Wang; Jun Wu; Yuming Guo; Dylan Tully; Ernest S Han; Susan E Yost; Yuan Yuan; John H Yim
Journal:  Cells       Date:  2019-08-30       Impact factor: 6.600

Review 4.  Signaling Proteins That Regulate Spermatogenesis Are the Emerging Target of Toxicant-Induced Male Reproductive Dysfunction.

Authors:  Sheng Gao; Xiaolong Wu; Lingling Wang; Tiao Bu; Adolfo Perrotta; Giuseppe Guaglianone; Bruno Silvestrini; Fei Sun; C Yan Cheng
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

Review 5.  PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression.

Authors:  Shuo Deng; Hin Chong Leong; Arpita Datta; Vennila Gopal; Alan Prem Kumar; Celestial T Yap
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

6.  Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential.

Authors:  Santosh Chauhan; Zahra Ahmed; Steven B Bradfute; John Arko-Mensah; Michael A Mandell; Seong Won Choi; Tomonori Kimura; Fabien Blanchet; Anna Waller; Michal H Mudd; Shanya Jiang; Larry Sklar; Graham S Timmins; Nicole Maphis; Kiran Bhaskar; Vincent Piguet; Vojo Deretic
Journal:  Nat Commun       Date:  2015-10-27       Impact factor: 14.919

7.  The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo.

Authors:  Gabriela Rozic; Lena Paukov; Jana Jakubikova; Dikla Ben-Shushan; Adrian Duek; Adi Leiba; Abraham Avigdor; Arnon Nagler; Merav Leiba
Journal:  Oncotarget       Date:  2016-09-20

8.  The dynactin subunit DCTN1 controls osteoclastogenesis via the Cdc42/PAK2 pathway.

Authors:  Yong Deok Lee; Bongjun Kim; Suhan Jung; Haemin Kim; Min Kyung Kim; Jun-Oh Kwon; Min-Kyoung Song; Zang Hee Lee; Hong-Hee Kim
Journal:  Exp Mol Med       Date:  2020-03-24       Impact factor: 8.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.